Third-line salvage chemotherapy in Hodgkin's disease

G. Bonadonna, S. Viviani, P. Valagussa, V. Bonfante, A. Santoro

Research output: Contribution to journalArticle

Abstract

CEP (CCNU, etoposide, and prednimustine) was tested as third-line chemotherapy in 40 patients resistant to both MOPP and ABVD. The observed response rate (complete remission, 35%, and partial remission, 25%) is encouraging. Treatment was generally well tolerated and all acute side effects were reversible.

Original languageEnglish
Pages (from-to)23-25
Number of pages3
JournalSeminars in Oncology
Volume12
Issue number1 SUPPL. 2
Publication statusPublished - 1985

Fingerprint

Prednimustine
Lomustine
Etoposide
Hodgkin Disease
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Bonadonna, G., Viviani, S., Valagussa, P., Bonfante, V., & Santoro, A. (1985). Third-line salvage chemotherapy in Hodgkin's disease. Seminars in Oncology, 12(1 SUPPL. 2), 23-25.

Third-line salvage chemotherapy in Hodgkin's disease. / Bonadonna, G.; Viviani, S.; Valagussa, P.; Bonfante, V.; Santoro, A.

In: Seminars in Oncology, Vol. 12, No. 1 SUPPL. 2, 1985, p. 23-25.

Research output: Contribution to journalArticle

Bonadonna, G, Viviani, S, Valagussa, P, Bonfante, V & Santoro, A 1985, 'Third-line salvage chemotherapy in Hodgkin's disease', Seminars in Oncology, vol. 12, no. 1 SUPPL. 2, pp. 23-25.
Bonadonna G, Viviani S, Valagussa P, Bonfante V, Santoro A. Third-line salvage chemotherapy in Hodgkin's disease. Seminars in Oncology. 1985;12(1 SUPPL. 2):23-25.
Bonadonna, G. ; Viviani, S. ; Valagussa, P. ; Bonfante, V. ; Santoro, A. / Third-line salvage chemotherapy in Hodgkin's disease. In: Seminars in Oncology. 1985 ; Vol. 12, No. 1 SUPPL. 2. pp. 23-25.
@article{aa2bf3ba73a24e1ca36510ac5280e630,
title = "Third-line salvage chemotherapy in Hodgkin's disease",
abstract = "CEP (CCNU, etoposide, and prednimustine) was tested as third-line chemotherapy in 40 patients resistant to both MOPP and ABVD. The observed response rate (complete remission, 35{\%}, and partial remission, 25{\%}) is encouraging. Treatment was generally well tolerated and all acute side effects were reversible.",
author = "G. Bonadonna and S. Viviani and P. Valagussa and V. Bonfante and A. Santoro",
year = "1985",
language = "English",
volume = "12",
pages = "23--25",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1 SUPPL. 2",

}

TY - JOUR

T1 - Third-line salvage chemotherapy in Hodgkin's disease

AU - Bonadonna, G.

AU - Viviani, S.

AU - Valagussa, P.

AU - Bonfante, V.

AU - Santoro, A.

PY - 1985

Y1 - 1985

N2 - CEP (CCNU, etoposide, and prednimustine) was tested as third-line chemotherapy in 40 patients resistant to both MOPP and ABVD. The observed response rate (complete remission, 35%, and partial remission, 25%) is encouraging. Treatment was generally well tolerated and all acute side effects were reversible.

AB - CEP (CCNU, etoposide, and prednimustine) was tested as third-line chemotherapy in 40 patients resistant to both MOPP and ABVD. The observed response rate (complete remission, 35%, and partial remission, 25%) is encouraging. Treatment was generally well tolerated and all acute side effects were reversible.

UR - http://www.scopus.com/inward/record.url?scp=0022415163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022415163&partnerID=8YFLogxK

M3 - Article

C2 - 2579440

AN - SCOPUS:0022415163

VL - 12

SP - 23

EP - 25

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1 SUPPL. 2

ER -